Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

technetium 99m HYNIC-duramycin

Known as: 99mTc-duramycin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Purpose Evaluation of [ 68 Ga]NODAGA-duramycin as a positron emission tomography (PET) tracer of cell death for whole-body… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2019
2019
Objective: To investigate the therapeutic efficacy of intratumoral injection of 125I-AA98 mAb for hepatocellular carcinoma (HCC… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
Duramycin is a heavily post-translationally modified peptide that binds phosphatidylethanolamine. It has been investigated as an… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Our goal was to validate the feasibility of 99mTc-duramycin as a potential apoptosis probe for monitoring tumor response to… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Review
2014
Review
2014
Since apoptosis plays an important role in maintaining homeostasis and is associated with responses to therapy, molecular imaging… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
INTRODUCTION (99m)Tc-Duramycin is a unique radiopharmaceutical that binds specifically to phosphatidylethanolamine (PE). The… 
Highly Cited
2011
Highly Cited
2011
We have previously shown that oxidative stress within the tumor microenvironment causes phosphatidylserine (PS) to redistribute… 
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2010
2010
New imaging agents are needed that home rapidly to tumors and saturate their target molecules with the unbound residue then… 
Highly Cited
2008
Highly Cited
2008
With only 19 amino acids, duramycin is the smallest known polypeptide that has a defined 3-dimensional binding structure… 
  • figure 1
  • figure 2
  • table 1
  • figure 3